|
 |
OrenciaThis page contains recent news articles, when available, and an overview of Orencia but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Bristol-Myers Squibb can now commercially produce the first major biologic drug that the company developed itself, Orencia, for rheumatoid arthritis, ... New York Times New Market Research Report from BioTrends Provides Insight on How ... - Dec 14, 2009 First line use was most common with Enbrel and Humira, while Rituxan and Orencia were more commonly later line choices. Despite an indication for use after ... PR Newswire (press release) EU Panel Backs DuoCover From Bristol-Myers Squibb Pharma - Dec 18, 2009 Orencia (abatacept), from Bristol-Myers Squibb Pharma EEIG, to extend the indication to include treatment of moderate to severe active polyarticular ... Wall Street Journal New and Upcoming Biologic Agents for Rheumatoid Arthritis - Dec 29, 2009 These agents include abatacept (Orencia, Bristol-Myers Squibb), which inhibits the activation of T-cells, and the popular cancer drug rituxamab (Rituxan, ... Ortho SuperSite Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent ... - Dec 23, 2009 ...anticipate that Actemra would be most likely to replace their infused products such as Centocor's Remicade and BMS's Orencia within their practices. ... PR Newswire (press release) The side effects - Dec 20, 2009 F. Orencia, a rheumatoid arthritis medication manufactured by Bristol-Meyers Squibb. advertising serves a vital health-care role by increasing people's ... Dubuque Telegraph Herald CHMP backs Amgen's Prolia and GSK's ITP drug - Dec 21, 2009 Temodal (temozolomide) for glioblastoma and extensions of indication for Roche's Herceptin (trastuzumab) and B-MS' Orencia (abatacept). ... Pharma Times CBG: positief advies voor DuoCover, negatief advies voor Cerepro - Dec 24, 2009 Voor Orencia (abatacept) werd de indicatie uitgebreid met “behandeling van matige tot ernstige actieve polyarticulaire juveniele idiopathische artritis bij ... Medical facts Bristol-Myers buys rights to RA drug $85 million - Nov 10, 2009 Bristol already sells the rheumatoid arthritis drug, Orencia, which generated sales of $434 million in the first nine months of this year, up 39 percent ... Reuters Bristol-Myers Squibb Releases Study Results that Support Orencia - Oct 22, 2009 The data from the Agree study, which compared patients treated with Orencia plus methotrexate versus patients treated with methotrexate alone, ... Trading Markets (press release) Bristol-Myers Squibb's Orencia Shows Sustained Clinical Response In Two-year ... - Oct 19, 2009 ...(BMY: News ) said data from a two-year study on its drug Orencia or abatacept, showed low disease activity, among other improvements, in patients with ... RTT News Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript - Nov 5, 2009 Current year royalty and other revenue benefited from a 28% increase in Orencia sales versus the same quarter last year. The company has continued to invest ... Seeking Alpha (blog) New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept ... - Oct 20, 2009 Bristol Myers-Squibb has a comprehensive development program underway to evaluate the potential subcutaneous administration of ORENCIA through an injection ... Reuters ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of ... - Oct 19, 2009 The data from the AGREE study, which compared patients treated with ORENCIA plus methotrexate versus patients treated with methotrexate alone, ... Reuters High Court rejects B-MS bid for NICE legal challenge - Nov 10, 2009 The cost watchdog ruled back in April last year that Orencia (abatacept) was simply too expensive for use on the NHS to treat patients with moderate-severe ... Pharma Times Maxygen Buying Back Stock; Analysts Say No Trend Here - Nov 13, 2009 ...s rheumatoid arthritis drug Orencia (abatacept), in a back-end loaded $170 million deal with Astellas Pharma Inc. The companies later expanded the deal into ... BioWorld Online Magnets for Arthritis - Nov 9, 2009 My dad, who was almost not able to golf and enjoy many other activities, is having incredible success with Orencia. He was on a clinical trial and now feels ... New York Times ACR: Abatacept Efficacy in RA Lasts for Two Years - Oct 23, 2009 PHILADELPHIA -- Abatacept (Orencia) is effective against clinical symptoms and joint erosion in early rheumatoid arthritis for at least two years, ... MedPage Today Money Briefs - Oct 20, 2009 NEW YORK — Bristol-Myers Squibb Co. said rheumatoid arthritis patients taking the drug Orencia plus a standard arthritis treatment had fewer signs of ... Worcester Telegram Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter - Oct 22, 2009 ORENCIA and SPRYCEL grew worldwide 36% and 30%, respectively as compared to the same period in 2008. * ERBITUX sales were down 3% compared to the third ... Reuters Merriman Curhan Ford Reiterates a 'Buy' on Repligen (RGEN); Slow & Steady Wins ... - Oct 28, 2009 ...including our clinical NPV of the pipeline and an NPV of the company's product revenue and royalty streams from Protein A and Orencia, respectively. ... StreetInsider.com (subscription) Bristol-Myers Squibb and Exelixis reveal trial results - Oct 27, 2009 Another Bristol-Myers Squibb trial into the rheumatoid arthritis drug Orencia showed that weekly administration of a 125 mg subcutaneous dose of the ... Zenopa Repligen Corp. Reports Operating Results (10-Q) - Nov 5, 2009 We have therefore begun recognizing royalty revenue in fiscal year 2009 for Bristol's net sales in the United States of Orencia® which is used in the ... GuruFocus.com In DTC TV, longer doesn't have to mean less memorable, says Nielsen - Nov 5, 2009 Rounding out the top five were spots for Wyeth's Pristiq (:75), Bristol- Myers Squibb/Sanofi-Aventis' Plavix (:60 and :75), and BMS's Orencia (:75). ... Medical Marketing and Media HGSI's Phase III Benlysta Details Boost Confidence in Second Trial - Oct 20, 2009 Bristol-Myers Squibb Co., of New York, presented data from an open-label study of rheumatoid arthritis drug Orencia (abatacept) showing minimal ... BioWorld Online New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With ... - Oct 19, 2009 ...or urinate more than normal -- feel very tired Tell your doctor about all the medications you take including ORENCIA (abatacept), KINERET (anakinra), ... Reuters Earnings for Two - Oct 22, 2009 Results were driven by Plavix (up 8%) and Abilify (up 16%), Baraclude (up 33%), Sustiva (up 7%), Reyataz (up 5%), Orencia (up 36%) and Sprycell (up 30%). ... TheStreet.com (subscription) Stay home with mild symptoms - Oct 31, 2009 Embrel, Remicade,, Humira, Orencia, CellCept Protopic, cancer chemotherapy, radiation therapy; under five years; pregnant, heart failure, liver failure, ... Brantford Expositor B-MS posts strong sales for most of its drugs - Oct 23, 2009 As for B-MS' newer drugs, Sprycel (dasatanib) for leukaemia rose 30% to $107 million, while Orencia (abatacept) for rheumatoid arthritis increased 36% to ... Pharma Times Drugmakers mostly post higher profits, muted sales - Oct 22, 2009 Psychiatric drug Abilify, Orencia for rheumatoid arthritis and hepatitis B drug Baraclude all had double-digit sales jumps. ... The Associated Press BMS paga até mil milhões de dólares por fármaco para artrite reumatóide - Nov 11, 2009 A BMS já comercializa o medicamento para a artrite reumatóide Orencia®, que gerou vendas de 434 milhões nos nove primeiros meses de 2009 e registou uma ... RCM Pharma «Bristol-Myers Squibb» готова отдать 1 млрд дол. за противоревматичеÑ?кий препарат - Nov 12, 2009 «Bristol-Myers Squibb» в наÑ?тоÑ?щее времÑ? уже маркетирует противоревматичеÑ?кий препарат Ñ?той же компании под торговой маркой Orencia ® (абатацепт), ... Аптека online Bristol-Myerså?‘表风湿性关节炎实验 - Oct 20, 2009 ...(BMY) 22.97 : BrIStol-Myers宣布最新临床数æ?®ï¼Œæ”¯æŒ?继ç»å¼€å?‘皮下注射剂ORENCIA (abatacept)，治疗ä¸åº¦ä¸Žä¸¥é‡?é£Žæ¹¿æ€§å…³èŠ‚ç‚Žç—…æ‚£ã€‚æœ¬ç ”ç©¶æ˜¾ç¤ºï¼Œæ¯?周注射一次125 mg ... 凤凰网 BMS, ê´€ì ˆì—¼ 치료í•ì²´ ë?„ìž… - Nov 10, 2009 ...ì?´ëŠ” 류마티스성 ê´€ì ˆì—¼ì—? 대해 2aìƒ? ìž„ìƒ?ì?„ 마친 ì œì œë¡œì„œ, BMS는 ALD518ì—? 대해 'ì˜¤ë Œì‹œì•„'(Orencia, abatacept) 등 기존 ì¹˜ë£Œì œë³´ë‹¤ë?„ 효과와 ì•ˆì „ì„±ì?´ ë›°ì–´ë‚ ... 디지틀보사 百时美施贵å®?第三å£è°ƒæ•´å?Žç›ˆåˆ©è¶…预期 - Oct 22, 2009 ...该公å?¸è¡¨ç¤ºï¼Œå‡ 款关键è?¯ç‰©çš„销售é¢?实现了å?Œä½?数增长，包括精神分裂症和èº?éƒ?ç—‡è?¯ç‰©Abilifyã€?风湿性关节炎è?¯ç‰©Orenciaã€?白血病è?¯ç‰©Sprycel，以å?Šä¹™åž‹è‚?ç‚Žè?¯ç‰©Baraclude。 ... 东方财富网 Bristol-Myers發表風濕性關節炎實驗 - Oct 20, 2009 ...(BMY: å ±åƒ¹) 22.97 : Bristol-Myers宣佈最新臨床數據，支æŒ?繼續開發皮下注射劑ORENCIA (abatacept)，治療ä¸åº¦èˆ‡åš´é‡?風濕性關節炎病患。 æœ¬ç ”ç©¶é¡¯ç¤ºï¼Œæ¯?週注射一次125 ... 環球財經 百时美施贵å®?第三å£è°ƒæ•´å?Žç›ˆåˆ©è¶…预期 - Oct 26, 2009 ...该公å?¸è¡¨ç¤ºï¼Œå‡ 款关键è?¯ç‰©çš„销售é¢?实现了å?Œä½?数增长，包括精神分裂症和èº?éƒ?ç—‡è?¯ç‰©Abilifyã€?风湿性关节炎è?¯ç‰©Orenciaã€?白血病è?¯ç‰©Sprycel，以å?Šä¹™åž‹è‚?ç‚Žè?¯ç‰©Baraclude。 ... 易富网 NICE says Bristol-Myers Orencia drug too costly - Aug 2, 2007 By Michael Kahn. LONDON (Reuters) - Bristol-Myers Squibb's rheumatoid arthritis drug Orencia should not be prescribed to people using the National Health ... Reuters UK Repligen reaches settlement with Bristol-Myers in Orencia patent... - Apr 8, 2008 BOSTON (Thomson Financial) - Repligen Corp. said Tuesday it reached a settlement with Bristol-Myers Squibb Co. in its patent lawsuit based on Bristol-Myers ... Forbes Bristol's Orencia can ease juvenile arthritis: study - Jul 15, 2008 By Michael Kahn. LONDON (Reuters) - Bristol-Myers Squibb Co's Orencia can help children with rheumatoid arthritis who do not respond to other drugs, ... Reuters India Bristol-Myers' Orencia Has 'Bullish Prospects' - Dec 13, 2005 Prudential Equity Group maintained an "underweight" rating on Bristol-Myers Squibb (nyse: BMY - news - people ) after the pharmaceutical firm held its ... Forbes Bristol's Orencia Approval Removes Uncertainty - May 9, 2006 UBS Investment Research reiterated a "neutral" rating on Bristol-Myers Squibb after the big pharma firm said federal health regulators approved an ... Forbes S.Korea's Celltrion gets FDA OK to make Bristol-Myers' Orencia - Dec 18, 2007 Dec 18 (Reuters) - South Korean biotech firm Celltrion Inc said it received approval from US health regulators to serve as a contract manufacturer to make ... Reuters UK's NICE again refuses to back Bristol's Orencia - Apr 23, 2008 LONDON, April 23 (Reuters) - Britain's healthcare cost-effectiveness watchdog has continued to recommend against prescribing Bristol-Myers Squibb Co's (BMY. ... Reuters Bristol-Myers Squibb Receives US Approval for Arthritis Drug - Dec 24, 2005 Bristol-Myers Squibb received federal clearance for its new drug Orencia ... Several analysts have said they expect Orencia to achieve blockbuster status. ... New York Times Bristol-Myers: Data from study suggests Orencia may delay development... - Jun 13, 2008 SAN FRANCISCO (Thomson Financial) - Bristol-Myers Squibb Co. said Friday results from an exploratory Phase II study suggest that Orencia may delay the ... Forbes High Hopes For Bristol-Myers' Orencia - Jun 23, 2006 The US drugmaker has high hopes for the rheumatoid arthritis treatment, which was approved by the US Food and Drug Administration last December and launched ... Forbes New drugs give hope to arthritis sufferers - Jun 13, 2007 Two - MabThera and Orencia - are already licensed in the UK, ... Orencia (abatacept) works in a different way, by interfering with the activation of T-cells ... Telegraph.co.uk Abbott faces a new rival in arthritis treatments - Sep 8, 2005 Orencia works via a mechanism that focuses on T-Cells, ... "We have looked at [Orencia] in a variety of patient populations and it has been effective in all ... Pay-Per-View - Chicago Tribune - ProQuest Archiver UK body says Bristol-Myers Orencia drug too costly - Aug 1, 2007 By Michael Kahn. LONDON, Aug 2 (Reuters) - Bristol-Myers Squibb Co.'s (BMY.N) rheumatoid arthritis drug Orencia should not be prescribed to people using ... Reuters Bristol-Myers Squibb Shares Look Expensive - Apr 26, 2006 Orencia will face competition from biotechnology leader Genentech (nyse: DNA ... "Rituxan and Orencia will directly compete with each other in anti-tumor ... Forbes A Big Test for 2 Drugs, and a Maker - Aug 24, 2005 While Orencia is widely expected to be recommended by its advisory panel - the FDA ... More certain for approval is the drug Orencia, a monthly infusion ... New York Times Bristol-Myers gets European approval for Orencia - May 23, 2007 LONDON, May 23 (Reuters) - Bristol-Myers Squibb (BMY.N) said on Wednesday the European Commission had granted approval for its rheumatoid arthritis drug ... Reuters ORENCIA(R) (Abatacept) or REMICADE(R)(Infliximab) Demonstrated … - Nov 14, 2006 WASHINGTON, Nov. 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results from a study providing further evidence of the efficacy, ... RedOrbit Rheumatoid Arthritis Drug May Improve Function - Sep 14, 2005 14, 2005 -- The experimental rheumatoid arthritis drug Orencia is safe and effective ... The researchers show that Orencia offered pain relief and increased ... WebMD FDA OKs Orencia for Juvenile Arthritis - Apr 10, 2008 By Kelli Miller Stacy. April 10, 2008 -- Children ages 6 and older living with a moderate to severe form of juvenile rheumatoid arthritis (JRA) have a new ... WebMD Study Results Supportive of Switching Directly to ORENCIA(R) - Jun 13, 2007 Barcelona (OTS) - According to a new study, it is possible to safely switch directly to ORENCIA(R) from anti-TNF therapy in rheumatoid arthritis patients ... ots.at Bristol-Myers Squibb to build manufacturing plant at Devens - Jun 1, 2006 The plant will produce biologic compounds used to make Orencia, a recently approved rheumatoid arthritis treatment, as well as experimental drugs that have ... Boston Globe Bristol-Myers Shares May Rise After US Clears Arthritis Drug - Dec 27, 2005 5 US drugmaker Bristol-Myers Squibb Co. may rise after its Orencia treatment ... The Food and Drug Administration approved Orencia for use in patients whose ... Bloomberg … Announces Submission of ORENCIA(R) (Abatacept) Supplemental … - Jan 3, 2006 PRINCETON, NJ, Jan. 3 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company announced today that it has completed submission of the supplemental Biologics ... RedOrbit Lonza extends supply deal with Bristol-Myers - Mar 12, 2007 N) rheumatoid arthritis drug Orencia until the end of 2013. ... Orencia, given by intravenous infusion, was launched in the United States last year. ... Reuters FDA Committee Backs Bristol Drug - Sep 6, 2005 Trial data suggest that Orencia, known generically as abatacept, improves the ... The advisory committee agreed that Orencia shouldn't be used jointly with ... TheStreet.com - TheStreet.com (subscription) ORENCIA(R) (Abatacept) Data Demonstrated Improvement in Children … - Nov 13, 2006 WASHINGTON, Nov. 13 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results of the double-blind phase of an ongoing study, ... RedOrbit ORENCIA(R) (Abatacept) Provided an Increasing Degree of Inhibition of... - Jun 12, 2008 Bristol-Myers Squibb Company (NYSE: BMY) today announced results of radiographic analyses from the AIM (Abatacept in Inadequate responders to Methotrexate) ... RedOrbit Arthritis drug approved - Aug 22, 2007 ...watchdog issued draft guidance rejecting free prescriptions of another cutting-edge drug, Orencia, for people suffering from rheumatoid arthritis. ... Independent Orencia Efficacy In Adults With Rheumatoid Arthritis, Two-year Data - Nov 11, 2006 Bristol-Myers Squibb Company (NYSE: BMY)today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ... Medical News Today - Medical News Today (press release) S&P Upgrades Univision to Strong Buy - Dec 27, 2005 The FDA approves Bristol-Myers' Orencia for rheumatoid arthritis. ... Orencia sales in 2006 could also be constrained by production capacity issues. ... BusinessWeek JoJo for short, Emiliano Fortunato Orencia Jr. ponders: What's in a... - Oct 17, 2006 My name is Emiliano Fortunato Orencia, Jr. My late father always told me to sign my full name on official documents like the SAT (can you imagine how ... Virginian-Pilot - Virginian Pilot ORENCIA® (abatacept) Supplemental Biologics License Application For … - Aug 12, 2007 Bristol-Myers Squibb Company (NYSE: BMY) today announced that the US Food and Drug Administration (FDA) has accepted, for filing and review, ... Medical News Today - Medical News Today (press release) Adverse events could still cast a shadow on Orencia's approval - Nov 1, 2005 Although Orencia appeared safe in clinical trials, long-term safety remains an issue. Bristol-Myers Squibb will conduct several post-marketing trials, ... Nature.com Launches of Humira, Golimumab and Orencia for Treatment of Ulcerative... - Aug 13, 2008 WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, ... RedOrbit Bristol-Myers Submits Orencia Supplemental Biologics License … - Aug 8, 2007 Bristol-Myers Squibb (BMS) announced that the FDA has accepted the supplemental biologics license application (sBLA) for Orencia for the treatment of ... FDA news - FDA news (subscription) Panel Recommends Drug - Sep 7, 2005 Abatacept will sell under the trade name Orencia if it gets FDA approval. During a hearing, the FDA Arthritis Advisory Committee agreed on a vote of 7 to 0 ... New York Times Arthritis sufferers denied 'last chance' as rationing body says drug... - Apr 24, 2008 Orencia is licensed for use in patients who have failed to respond to other medication, including the most advanced current drugs. ... Daily Mail Bristol-Myers to build $660 million plant for biotech drugs - Mar 8, 2006 Deutsche Bank analyst Barbara Ryan said the new plant is a logical step because one of Bristol-Myers' key new products, Orencia, is a biotech drug as are ... San Diego Union - Tribune - San Diego Union Tribune EULAR: Abatacept (Orencia) More Durable in RA than Infliximab ( … - Jun 16, 2008 By Michael Smith, North American Correspondent, MedPage Today. PARIS, June 16 -- Two different biologic approaches to rheumatoid arthritis -- abatacept ... MedPage Today FDA Approves Orencia(R) (Abatacept) For Rheumatoid Arthritis … - Dec 26, 2005 Bristol-Myers Squibb Company (NYSE: BMY) announced today that the US Food and Drug Administration (FDA) has approved Orencia(R) (abatacept), ... Medical News Today - Medical News Today (press release) … Files Infringement Complaint Against Bristol-Myers Squibb for... - Jan 6, 2006 On December 23, 2005, the US Food and Drug Administration (FDA) approved BMS' application to market CTLA4-Ig, under the brand name Orencia(R), for treatment ... Free with registration - PR Newswire - AccessMyLibrary.com … Re-Establishment of Clinical Improvement with Orencia® in Children... - Jun 18, 2007 Everyone in Period C received 10 mg/kg of ORENCIA approximately every 28 days. ... All SAEs were considered unrelated to ORENCIA according to the ... Medical News Today - Medical News Today (press release) FDA Approvals: Orencia and Revlimid - Dec 29, 2005 Dec. 29, 2005 — The US Food and Drug Administration (FDA) has approved abatacept injection for the treatment of moderately to severely active rheumatoid ... Medscape New Two-year ORENCIA® (abatacept) AIM Data Presented At Annual … - Jun 23, 2006 In an analysis of the AIM Long-Term Extension (LTE) (Kremer, et al) clinical outcomes were based on the percent of people achieving ACR 20, 50 and 70 scores ... webwire.com NICE snubs Orencia, picks 3 rivals - Oct 26, 2007 It's final: Britain's National Health Service won't pay for Bristol-Myers Squibb's anti-arthritis drug Orencia. Patient advocacy groups had been lobbying ... FiercePharma … US Food and Drug Administration Approves ORENCIA(R) (abatacept)... - Apr 8, 2008 US Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in ... Pay-Per-View - PR Newswire - HighBeam Research Stocks Set to Pop - Dec 23, 2005 The intravenously administered drug, abatacept, will be sold under the name Orencia. Elsewhere, Dynegy (DYN - commentary - Cramer's Take) closed another ... TheStreet.com - TheStreet.com (subscription) New Two-Year Orencia(R) (abatacept) Aim Data Presented At Annual … - Jun 26, 2006 Data presented at the 2006 European League Against Rheumatism (EULAR) annual congress looked at the Bristol-Myers Squibb Company (NYSE: BMY) rheumatoid ... Medical News Today - Medical News Today (press release) ORENCIA(R) (Abatacept) Supplemental Biologics License Application for... - Aug 7, 2007 NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) has accepted, ... RedOrbit Bristol-Myers Squibb's Plavix In Q2 Spotlight - Jul 25, 2006 ..."We view initial Orencia/Sprycel launch updates and any Plavix FTC commentary as the most important takeaways from Bristol's conference call," the analyst ... Forbes … Patients With Early Erosive Rheumatoid Arthritis Treated With... - Oct 27, 2008 This study showed that ORENCIA ® (abatacept) in combination with MTX had ... The safety profile of ORENCIA in combination with MTX was similar to that of ... International Business Times Data Demonstrate Efficacy, Safety With ORENCIA In Adults With … - Nov 10, 2007 Bristol-Myers Squibb Company announced that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term ... emaxhealth.com The Sun, Lowell, Mass., Dan O'Brien column. - Jun 4, 2006 There it will produce compounds used to make a drug called Orencia. If you're not associated with anyone who is suffering from rheumatoid arthritis, ... Free with registration - The Sun - AccessMyLibrary.com … Long-Term Efficacy And Safety With ORENCIA® (abatacept) In Adults ... - Nov 12, 2007 The data show that, in these patients, ORENCIA provided sustained ... "These data are important because they show that ORENCIA is efficacious and has an ... Medical News Today - Medical News Today (press release) Abatacept, marketed as Orencia appears to offer pain relief and... - Sep 21, 2005 A new drug appears to offer pain relief and increased mobility to rheumatoid arthritis patients who have exhausted their other medical treatment options. ... News-Medical.net B-MS completes Orencia sBLA.(Bristol-Myers Squibb Co.)(Brief Article) - Jan 9, 2006 US drug major Bristol-Myers Squibb has completed the submission of a supplemental Biologics License Application to the US Food and Drug Administration for ... Free with registration - Pharma Marketletter - AccessMyLibrary.com FDA Approves Orencia (abatacept) for Children with JIA - Apr 14, 2008 As of last week, parents will have one more option to help their children battle Juvenile Idiopathic Arthriti (JIA). The FDA has approved Orencia ... HealthCentral.com Drugs in testing show promise for treating lupus - Jan 23, 2007 Bristol-Myers is conducting late-stage trials with Orencia, ... Orencia, which is administered about every 28 days via a 30-minute intravenous infusion, ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette BMS Seeks Approval to Boost Orencia Production - Jan 4, 2006 Bristol-Myers Squibb has completed the submission of its supplemental biologics license application to the FDA for the licensure of a third-party ... RedOrbit ORENCIA® (abatacept) Data Demonstrated Improvement In Children And … - Nov 15, 2006 Bristol-Myers Squibb Company (NYSE: BMY) today announced results of the double-blind phase of an ongoing study, which show ORENCIA® (abatacept) demonstrated ... Medical News Today - Medical News Today (press release) … Drug Administration Approves ORENCIA(R) (abatacept) Supplemental … - May 5, 2006 US Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility ... Pay-Per-View - PR Newswire - HighBeam Research B-MS's Orencia performs well in trials.(product development)(Brief... - May 15, 2006 USA-based drug major Bristol-Myers Squibb says that data from trials of its drug Orencia (abatacept), in rheumatoid arthritis patients who show inadequate ... Free with registration - Pharma Marketletter - AccessMyLibrary.com ORENCIA(R) (Abatacept) Demonstrates Continued Improvement in … - Jun 13, 2007 Barcelona (OTS) - Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of ... ots.at Article: Orencia, Boniva injection.(New & Approved) - Skin & Allergy... - Mar 1, 2006 Orencia, Boniva injection.(New & Approved) ... find Skin & Allergy News articles. Orencia (abatacept, Bristol-Meyers Squibb Co.) A novel biologic agent that ... Pay-Per-View - Skin & Allergy News - HighBeam Research EULAR: Orencia (abatacept) Inhibits Long-Term RA Progression - Jun 23, 2006 By Judith Groch, Senior Writer, MedPage Today. AMSTERDAM, The Netherlands, June 23 — Two-year data from the extension of a major trial of Orencia ... MedPage Today Article: Orencia.(New & Approved)(Brief Article) - Family Practice... - Feb 15, 2006 Orencia.(New & Approved)(Brief Article) ... find Family Practice News articles. Orencia (abatacept, Bristol-Meyers Squibb) A novel biologic agent that ... Pay-Per-View - Family Practice News - HighBeam Research … Announces Submission of ORENCIA(R) (abatacept) Supplemental … - Jan 3, 2006 Bristol-Myers Squibb Company Announces Submission of ORENCIA(R) (abatacept) Supplemental Biologics License Application to the US Food and Drug ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) … - Nov 14, 2006 ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy ... Pay-Per-View - PR Newswire - HighBeam Research Orencia . - Sep 28, 2008 RA such as enbrel Remicade', humira or kineret Taking ORENCIA with biologies for ... ORENCIA can cause serious side effects including serious infections and ... Lawrence Journal-World - Google News Archive Studies Assess Effectiveness of Orencia and Humira in Children with... - Nov 21, 2006 Two studies recently presented at the American College of Rheumatology's annual meeting in Washington showed that Orencia and Humira, drugs approved for ... HealthCentral.com Tax credits, with strings attached Bill would allow state to 'recaptur... - Jun 20, 2006 ...could invest as much as $1.1 billion at Devens depending on demand for the drugs it will develop, including Orencia, which treats Rheumatoid arthritis. ... Free with registration - The Sun - AccessMyLibrary.com FDA clears Lonza for Orencia production - May 23, 2006 By Gregory Roumeliotis, 23-May-2006. Lonza has been authorised by the US Food and Drug Administration (FDA) to produce Bristol-Myers Squibb's arthritis drug ... OutSourcing-Pharma.com Bristol-Myers Squibb Announces Quebec Adds Orencia to List of … - Jun 26, 2007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. ... $4.95 - M2 Presswire - ECNext US Food and Drug Administration approves Orencia (abatacept) … - May 5, 2006 Bristol-Myers Squibb Co announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics Licence Application (sBLA) for the ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Bristol-Myers Squibb closes on Devens land - Feb 19, 2007 The new manufacturing facility will allow Bristol-Myers to expand its capacity to produce a commercial drug called Orencia. ... Bizjournals.com Orencia.(New & Approved)(Brief Article) - Feb 15, 2006 A novel biologic agent that inhibits activation of T cells, for reducing signs and symptoms, inducing major clinical response, slowing progression of ... Free with registration - Family Practice News - AccessMyLibrary.com Orencia approved for rheumatoid arthritis.(Brief article) - Mar 1, 2006 The federal Food and Drug Administration (FDA) approved abatacept (Orencia), a new drug in an all-new class of biologic drugs known as costimulation ... Free with registration - HealthNews - AccessMyLibrary.com … Demonstrated a Re-Establishment of Clinical Improvement with Orenci... - Jun 15, 2007 Everyone in Period C received 10 mg/kg of ORENCIA approximately every 28 days. ... All SAEs were considered unrelated to ORENCIA according to the ... Free with registration - M2 Presswire - AccessMyLibrary.com Orencia gets FDA nod for treatment of rheumatoid arthritis. - Jan 9, 2006 Orencia gets FDA nod for treatment of rheumatoid arthritis. Bristol-Myers Squibb has received the green light from the FDA for Orencia (abatacept), ... $9.94 - Drug Topics - Alacra Store FDA Approves Labeling Update For ORENCIA To Inhibit Structural Joint ... - Apr 29, 2007 ...(April 29, 2007)-- Myers Squibb Company announced that the US Food and Drug Administration (FDA) has approved an update to the ORENCIA (abatacept) product ... Compliance Home - Compliance Home … Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit. - PR … - Apr 8, 2008 Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research EC clears B-MS' Orencia for RA.(European Commission)(Bristol-Myers … - Jun 4, 2007 The European Commission has granted approval of US drug major Bristol-Myers Squibb's Orencia (abatacept) for rheumatoid arthritis, a disease that may affect ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … Squibb Reviews Sprycel, Apixaban and Orencia After Major Medical … - Dec 18, 2006 OPERATOR: Good day and welcome to today's Post-ASH Investor Call. This call is being recorded. At this time, I'd like to turn the call over to Mr. John ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Orencia.(Drug therapy for rheumatoid arthritis )(Brief Article) |... - Feb 15, 2006 Orencia.(Drug therapy for rheumatoid arthritis )(Brief Article) ... find Internal Medicine News articles. Orencia (abatacept, Bristol-Meyers Squibb) A novel ... Pay-Per-View - Internal Medicine News - HighBeam Research Bristol-Myers Squibb.(drug approval for Orencia)(Brief Article) - Jan 16, 2006 Bristol-Myers Squibb gained Food and Drug Administration approval last month for Orencia, a new treatment for rheumatoid arthritis. ... Free with registration - Drug Store News - AccessMyLibrary.com Strong long-term efficacy and safety data for Orencia. - Nov 19, 2007 US drug major Bristol-Myers Squibb says that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Press Release: Two-Year Data for ORENCIA(R) (abatacept) Demonstrate … - Nov 9, 2006 Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Clinical Improvement with Orencia(R) (Abatacept) in … - Jun 15, 2007 Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research Bristol-Myers cites Orencia study - Jun 15, 2007 By : Agencies. NEW YORK (AP) - Bristol-Myers Squibb Co. said Friday an investigational study of Orencia showed that it may be effective in treating the most ... ABCmoney.co.uk Bristol-Myers Squibb Completes Land Acquisition for New Biologics … - Feb 16, 2007 The new Devens manufacturing facility is expected to support increased production capacity for commercially available biologic compounds, such as ORENCIA(R) ... Genetic Engineering News - Genetic Engineering News (press release) Devens board OKs permit for Bristol-Myers - Oct 26, 2006 McKenzie said the plant will create components for the drug Orencia, which aids those who suffer from rheumatoid arthritis. Later, Jeff Sarvis, director of ... $2.95 - The Sun - NewsBank Press Release: ORENCIA(R) (abatacept) Data Demonstrated … - Nov 13, 2006 ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR ... Pay-Per-View - PR Newswire - HighBeam Research Post Hoc Data Show Daily Activity Participation, Independence And... - Nov 15, 2007 Poster presentations of these analyses of the AIM (n=433 for ORENCIA plus MTX; ... Patients who were treated with ORENCIA were compared with those in the ... Medical News Today - Medical News Today (press release) Abatacept Data Demonstrated Improvement in Children and Adolescents … - Nov 20, 2006 In addition, no child receiving Orencia during the six-month double-blind ... The study, designed to assess the efficacy and safety of Orencia in children ... DG News … : European Commission Grants Approval for ORENCIA(R) (abatacept)... - May 23, 2007 European Commission Grants Approval for ORENCIA(R) (abatacept) for Treatment of Rheumatoid Arthritis. from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research FDA Approves Abatacept (Orencia) for Juvenile Idiopathic Arthritis - Apr 9, 2008 By Kristina Fiore, Staff Writer, MedPage Today. PRINCETON, NJ, April 9 -- The FDA has approved abatacept (Orencia), a rheumatoid arthritis agent, ... MedPage Today … Positive Data from 2-Year Phase III Trials of ORENCIA for Treatment... - Nov 9, 2006 The data also demonstrate that ORENCIA provided clinically meaningful improvements ... ORENCIA is indicated for reducing signs and symptoms, inducing major ... StreetInsider.com - StreetInsider.com (subscription) US FDA advisers urge appro of B-MS' Orencia.(Bristol-Myers Squibb Co.) - Sep 12, 2005 The Arthritis Drugs Advisory Committee of the US Food and Drugs Administration voted unanimously on September 6 that the agency should approve US drug major ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Bristol-Myers says Orencia shows 'long-term efficacy and safety' - Nov 9, 2007 By : Agencies. BOSTON (Thomson Financial) - Bristol-Myers Squibb Co. said Friday that five-year data on Orencia (abatacept) demonstrates 'long-term efficacy ... ABCmoney.co.uk Orencia (abatacept) from Bristol-Myers Squibb (www.orencia.com) has … - May 12, 2008 Orencia (abatacept) from Bristol-Myers Squibb (www.orencia.com) has been approved by the FDA for reducing signs and symptoms in pediatric patients six years ... $9.94 - Drug Topics - Alacra Store |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |